AI Article Synopsis

  • The study aimed to assess the effectiveness of human recombinant endostatin (Endostar®) in combination with cisplatin doublets for treating advanced non-small cell lung cancer (NSCLC) and to use CT perfusion imaging for evaluating outcomes.
  • Conducted from April 2011 to September 2014, 76 NSCLC patients were split into two groups: one received Endostar® before chemotherapy (group A), while the other received it from the start of treatment (group B).
  • Results showed a statistically significant difference in treatment effectiveness between the two groups, with group A showing better outcomes; CT perfusion imaging proved useful for assessing the results, while adverse reactions were similar in both groups.

Article Abstract

Aims: To study the effectiveness of human recombinant endostatin injection (Endostar®) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging.

Methods: From April 2011 to September 2014, 76 patients with advanced NSCLC who were treated with platinum-based doublets were divided into group A (36 patients) and group B (40 patients). Endostar® 15 mg/day was administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A, and combined with chemotherapy from the first day in Group B. Endostar® in the two groups was injected intravenously for 14 days.

Results: Treatment effectiveness in the two groups differed with statistical significance (p<0.05). Effectiveness evaluated by CT perfusion imaging, BF, BV, MTT and PS also demonstrated significant differences (all p<0.05). Adverse reactions in the two groups did not significantly vary (p>0.05).

Conclusions: The response rate with Endostar® administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A was better than Endostar® combined with chemotherapy from the first day, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.7314/apjcp.2015.16.15.6765DOI Listing

Publication Analysis

Top Keywords

human recombinant
8
recombinant endostatin
8
combined cisplatin
8
doublets treating
8
patients advanced
8
advanced nsclc
8
group patients
8
combined chemotherapy
8
chemotherapy day
8
day group
8

Similar Publications

Reducing Healing Period with DDM/rhBMP-2 Grafting for Early Loading in Dental Implant Surgery.

Tissue Eng Regen Med

January 2025

Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital, 172 Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea.

Background: Traditionally, dental implants require a healing period of 4 to 9 months for osseointegration, with longer recovery times considered when bone grafting is needed. This retrospective study evaluates the clinical efficacy of demineralized dentin matrix (DDM) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) during dental implant placement to expedite the osseointegration period for early loading.

Methods: Thirty patients (17 male, 13 female; mean age 55.

View Article and Find Full Text PDF

We identified seven distinct coronaviruses (CoVs) in bats from Brazil, classified into 229E-related (Alpha-CoV), Nobecovirus, Sarbecovirus, and Merbecovirus (Beta-CoV), including one closely related to MERS-like CoV with 82.8% genome coverage. To accomplish this, we screened 423 oral and rectal swabs from 16 different bat species using molecular assays, RNA sequencing, and evolutionary analysis.

View Article and Find Full Text PDF

Biochips are widely applied to manipulate the geometrical morphology of stem cells in recent years. Patterned antenna-like pseudopodia are also probed to explore the influence of pseudopodia formation on gene delivery and expression on biochips. However, how the antenna-like pseudopodia affect gene transfection is unsettled and the underlying trafficking mechanism of exogenous genes in engineered single cells is not announced.

View Article and Find Full Text PDF

Background: While vaccination remains crucial in mitigating the impact of the COVID-19 pandemic, several ocular adverse events has been reported, including Acute Zonal Occult Outer Retinopathy (AZOOR) complex.

Case Presentation: A 31-year-old female presented declined best corrected visual acuity (BCVA) and flashes in both eyes three days following second recombinant mRNA COVID-19 vaccine (Moderna). Fundus autofluorescence (FAF) illustrated speckled hyper-AF lesions surrounding right eye torpedo maculopathy site and hyper-AF lesions in the left macula.

View Article and Find Full Text PDF

Combined negative pressure wound therapy with new wound dressings to repair a ruptured giant omphalocele in a neonate: a case report and literature review.

BMC Pediatr

January 2025

Department of Neonatology Nursing, West China Second University Hospital, Sichuan University, No. 20, Section 3, South Renmin Road, Chengdu, Sichuan Province, China.

Background: Current treatment of giant omphalocele in newborns is not standardized. The main treatments include one-time repair and staged surgery using synthetic and biologic mesh, or silos. However, surgery can lead to various postoperative complications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!